Our Experts

At NDA we’re a team of experts – experts in the regulated disciplines, and experts in drug development.

Some of us have attained our experience from working inside regulatory authorities, carefully assessing the benefits and risks of new treatments. Some of us have worked for years in the biotech and pharmaceutical industry, patiently developing life changing products for patients suffering from debilitating and sometimes deadly diseases and conditions.

Whatever our background, we share a passion for the art and science of drug development and for making a difference to the clients and the patients we ultimately serve.

Get to know the people behind the passion – read more about our incredible team below.

All services Development Strategy Medical Devices Pharmacovigilance Strategic Communications Regulatory Quality & Compliance NDA Advisory Board
All expertise Oncology Vaccine Immunogenicity HTA In-Vitro Diagnostics Non-Clinical Cell and Gene Therapy Paediatric Clinical CMC Market Access Rare Disease ATMP Cardiology Biostatistics Acceleration Strategies Medical Devices Patient Safety Quality Bioanalysis
01-10-2020

Dr Mel Walker

Advisory Board Member
Expert in commercial strategy, market access, pricing and reimbursement
Read More
01-10-2020

Dr Olivier Wong

Advisory Board Member
Expert in study design from an HTA and payer perspective
Read More
01-10-2020

Dr Thomas Lönngren

Strategic Advisor
Expert in the EU regulatory system and global regulatory strategies
Read More
01-10-2020

Dr Yngve Mikkelsen

Advisory Board Member
Expert in development strategy, market access, HTA and reimbursement
Read More
01-10-2020

Professor Carole Longson

Advisory Board Member
Expert in Science policy, market access, pricing and reimbursement
Read More
02-10-2020

Professor Félix Lobo

Advisory Board Member
Expert in health economics and the pharmaceutical industry
Read More
01-10-2020

Professor J.-Matthias Graf von der Schulenburg

Advisory Board Member
Expert in pricing and reimbursement with a special focus on Germany
Read More
01-10-2020

Professor Peter Kolominsky-Rabas

Advisory Board Member
Expert in HTA, market access, and real-world evidence
Read More

Contact Us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.

This website uses cookies

Cookies ("cookies") consist of small text files. The text files contain data which is stored on your device. To be able to place some type of cookies we need your consent. We at NDA Group AB, corporate identity number 556654-3046 use these types of cookies. To read more about which cookies we use and storage duration, click here to get to our cookiepolicy.

Manage your cookie-settings

Necessary cookies

Necessary cookies are cookies that need to be placed for fundamental functions on the website to work. Fundamental functions are for instance cookies that are needed for you to use menus and navigate the website.

Statistical cookies

To know how you interact with the website we place cookies to collect statistics. These cookies anonymize personal data.

Ad measurement cookies

To be able to provide a better service and experience we place cookies to tailor marketing for you. Another purpose for this placement is to market products or services to you, give tailored offers or market and give recommendations on new concepts based on what you have bought from us previously.
Confirm choices Accept all